Literature DB >> 24103733

Inhibiting cardiac allograft rejection with interleukin-35 therapy combined with decitabine treatment in mice.

Hao Guo1, Wei Wang, Na Zhao, Xianghui He, Liwei Zhu, Xueming Jiang.   

Abstract

BACKGROUND: Regulatory T (Treg) cells play a pivotal role in the maintenance of transplantation tolerance. It is of great interest to induce allograft tolerance mediated by regulatory CD4(+)CD25(+) T cells.
METHODS: Here we investigated the effect of hydrodynamic IL-35-expressing plasmid injection in combination with a methyltransferase inhibitor (decitabine) on immune function and transplantation tolerance in mice.
RESULTS: We showed that IL-35 and decitabine stimulated the proliferation of CD4(+)CD25(+) Tregs and suppressed CD8(+) T cell proliferation in an allogenic mixed lymphocyte culture in vitro. IL-35 gene therapy and decitabine administration prolonged the survival of the transplanted heart in the heterotopic abdominal heart transplantation model in mice.
CONCLUSIONS: The possible mechanism through which IL-35 and decitabine treatment increased the survival of graft tissues is to enhance the proliferation of CD4(+)CD25(+) Treg cells and suppress the generation and function of effector T cells. Thus, IL-35 gene therapy combined with decitabine provides a novel approach to induce transplantation tolerance.
© 2013.

Entities:  

Keywords:  5-Aza-2′-deoxycytidine; Aza; CD4(+)CD25(+) Treg cell; Cardiac allograft; DNA methyltransferase; DNMT; Decitabine; FCM; Flow cytometry; IL-35; MLR; Mixed leukocyte reaction; Regulatory T cells; Treg

Mesh:

Substances:

Year:  2013        PMID: 24103733     DOI: 10.1016/j.trim.2013.10.001

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  7 in total

Review 1.  Epigenetic drug discovery: breaking through the immune barrier.

Authors:  David F Tough; Paul P Tak; Alexander Tarakhovsky; Rab K Prinjha
Journal:  Nat Rev Drug Discov       Date:  2016-10-21       Impact factor: 84.694

2.  Decitabine inhibits T cell proliferation via a novel TET2-dependent mechanism and exerts potent protective effect in mouse auto- and allo-immunity models.

Authors:  Xue Wang; Jun Wang; Yong Yu; Tonghui Ma; Ping Chen; Bing Zhou; Ran Tao
Journal:  Oncotarget       Date:  2017-05-22

3.  The DNA Methylation Inhibitor Zebularine Controls CD4+ T Cell Mediated Intraocular Inflammation.

Authors:  Yanli Zou; Xiao Hu; Lauren P Schewitz-Bowers; Madeleine Stimpson; Li Miao; Xiaofei Ge; Liu Yang; Yan Li; Paul W Bible; Xiaofeng Wen; Jing Jing Li; Yizhi Liu; Richard W J Lee; Lai Wei
Journal:  Front Immunol       Date:  2019-08-16       Impact factor: 7.561

4.  Immune responses to azacytidine in animal models of inflammatory disorders: a systematic review.

Authors:  Sija Landman; Chiel van der Horst; Piet E J van Erp; Irma Joosten; Rob de Vries; Hans J P M Koenen
Journal:  J Transl Med       Date:  2021-01-06       Impact factor: 5.531

Review 5.  Approaches for Controlling Antibody-Mediated Allograft Rejection Through Targeting B Cells.

Authors:  Yoshiko Matsuda; Takeshi Watanabe; Xiao-Kang Li
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

6.  Effects of an intravitreal injection of interleukin-35-expressing plasmid on pro-inflammatory and anti-inflammatory cytokines.

Authors:  Chao Hou; Qianni Wu; Chen Ouyang; Ting Huang
Journal:  Int J Mol Med       Date:  2016-07-22       Impact factor: 4.101

Review 7.  Mesenchymal stem cells overexpressing IL-35: a novel immunosuppressive strategy and therapeutic target for inducing transplant tolerance.

Authors:  Hao Guo; Baozhu Li; Wei Wang; Na Zhao; Haopeng Gao
Journal:  Stem Cell Res Ther       Date:  2018-09-26       Impact factor: 6.832

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.